Glypican 3 antibody drug conjugate - Bristol-Myers Squibb

Drug Profile

Glypican 3 antibody drug conjugate - Bristol-Myers Squibb

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Glypican 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 14 Feb 2017 Phase-I clinical trials in Cancer in USA (Parenteral) before February 2017 (Bristol-Myers Squibb pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top